Pfizer Inc  (PFE)
Other Ticker:  

Pfizer Inc Segments

Cardiovascular & metabolic diseases
   7.34 % of total Revenue
Central nervous system disorders
   1.23 % of total Revenue
Arthritis & pain
   1.62 % of total Revenue
Infectious & respiratory diseases
   4.91 % of total Revenue
   2.55 % of total Revenue
   2.14 % of total Revenue
   0.75 % of total Revenue
Endocrine disorders
   1.09 % of total Revenue
All other
   69.99 % of total Revenue
Total Pharmaceutical
   91.61 % of total Revenue
Consumer Healthcare and Vaccines
   6.25 % of total Revenue

Business Segments (Sep. 30, 2015)
(in millions $)
III. Quarter
(of total Revenues)
(Sep. 30, 2015)
(in millions $)
III. Quarter
(Profit Margin)
Cardiovascular & metabolic diseases
959.00 7.34 % 0.00 -
Central nervous system disorders
161.00 1.23 % 0.00 -
Arthritis & pain
212.00 1.62 % 0.00 -
Infectious & respiratory diseases
641.00 4.91 % 0.00 -
333.00 2.55 % 0.00 -
279.00 2.14 % 0.00 -
98.00 0.75 % 0.00 -
Endocrine disorders
142.00 1.09 % 0.00 -
All other
9,146.00 69.99 % 0.00 -
Total Pharmaceutical
11,971.00 91.61 % 0.00 -
Consumer Healthcare and Vaccines
817.00 6.25 % 0.00 -
13,067.00 100 % 0.00 -

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (Sep. 30, 2015)
Y/Y Revenue
III. Quarter
Q/Q Revenue
(Sep. 30, 2015)
Y/Y Income
III. Quarter
Q/Q Income
Cardiovascular & metabolic diseases
-49.12 % 40.62 % - -
Central nervous system disorders
-90.44 % -87.73 % - -
Arthritis & pain
-72.25 % -5.36 % - -
Infectious & respiratory diseases
-49.45 % 31.08 % - -
-30.77 % -25.67 % - -
-2.79 % -60.87 % - -
-20.97 % -1.01 % - -
Endocrine disorders
-17.92 % -14.97 % - -
All other
223.18 % 105.39 % - -
Total Pharmaceutical
23.04 % 39.41 % - -
Consumer Healthcare and Vaccines
-67.46 % -66.24 % - -
5.71 % 10.24 % - -

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Pfizer Inc's Cardiovascular & metabolic diseases, Central nervous system disorders, Arthritis & pain, Infectious & respiratory diseases, Urology, Oncology, Ophthalmology, Endocrine disorders, All other, Total Pharmaceutical, Consumer Healthcare and Vaccines, Total segment. Select each division with the arrow.

  Pfizer Inc's

Business Segments Description

Business Segments

We operate in three business segments: Pharmaceutical, Consumer Healthcare and Animal Health.

Pharmaceutical Segment

Our Pharmaceutical business is the largest in the world. This segment includes treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies.

Our principal pharmaceutical products and certain recently approved products are as follows:

Cardiovascular and Metabolic Diseases

• Lipitor, our largest-selling product, is for the treatment of elevated cholesterol in the bloodstream. It is the most-prescribed medicine of any kind in the world.

• Norvasc is for the treatment of hypertension (high blood pressure) and angina (heart pain). It is the world’s most-prescribed branded medicine for the treatment of hypertension and angina and the fourth-largest selling drug of any kind in the world.

• Caduet, a dual therapy medicine, was approved by the FDA on January 30, 2004. Caduet contains Lipitor for the treatment of

high cholesterol and Norvasc for the treatment of high blood pressure. We submitted an application in the European Union (EU) for Caduet in December 2003.

• Accupril/Accuretic is an angiotensin converting enzyme (ACE) inhibitor for the treatment of hypertension and congestive heart failure.

• Cardura is for the treatment of hypertension and benign prostatic hyperplasia (enlarged prostate gland).

• Glucotrol XL is for the treatment of diabetes. It is an oral medicine that stimulates the pancreas to produce more insulin.

• Inspra, for the treatment of congestive heart failure in patients who have had a heart attack, was approved by the FDA in October 2003. The product was launched for this indication in the U.S. in January 2004.

Central Nervous System Disorders

•Zoloft is the most-prescribed selective serotonin re-uptake inhibitor in the U.S. It is for the treatment of depression, panic disorder, obsessive-compulsive disorder in adults and children, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (SAD). Zoloft is approved for acute and long-term use in all of these indications except PMDD and is the only approved drug for the long-term treatment of PTSD and SAD.

• Neurontin is a leading epilepsy medicine, approved as an add-on therapy with other anti-epileptic medications to treat partial seizures in patients over three years of age. It also is approved in more than 60 markets for the treatment of a range of neuropathic pain conditions. In addition, Neurontin is the first oral medication approved in the U.S. for the treatment of post-herpetic neuralgia, a persistent, painful condition that afflicts many people in the aftermath of shingles.

• Geodon, which is marketed under the trademark Zeldox in many countries outside the U.S., is for the treatment of symptoms associated with schizophrenia. It has been approved in 64 countries and launched in the U.S., Germany, Spain, Brazil and other major markets. It is the first and only atypical antipsychotic available in both an oral and a rapid-acting, intramuscular dosage form.

• Aricept, discovered and developed by Eisai Co., Ltd., is the world’s leading medicine to treat symptoms of Alzheimer’s disease. We copromote Aricept with Eisai in the U.S. and several other countries and have an exclusive license to sell the drug in certain other countries.

• Xanax is for the treatment of generalized anxiety disorder and panic disorder. Xanax XR, an extended-release formulation of the drug, is a rapid-acting, once-a-day medication approved for treating panic disorder. Xanax XR was approved by the FDA and launched in the U.S. in 2003.

• Relpax is an oral treatment for acute migraine headaches. It has been launched in more than 25 countries, including the U.S., where it was launched in March 2003, Japan and throughout Europe.

• Rebif, discovered and developed by Serono S.A., is for the treatment of relapsing forms of multiple sclerosis. We copromote Rebif with Serono in the U.S.

Arthritis and Pain

• Celebrex is for the treatment of osteoarthritis, rheumatoid arthritis, acute pain and menstrual pain. It also is approved in the U.S. and the EU for the treatment of familial adenomatous polyposis. Celebrex has the broadest range of approved indications of any selective COX-2 inhibitor and is the most-prescribed arthritis brand in the U.S.

• Bextra is for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain. It was launched in the U.S. in 2002 and in the EU in 2003 and also has been launched in Canada and most of Latin America.

Infectious and Respiratory Diseases

• Zithromax is the largest-selling antibiotic in the world. It is the only available single-dose treatment for middle ear infection in the U.S., and the Zithromax Tri-Pak dosage form is the first and only three-day regimen for the treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease. On January 20, 2004, we announced that the FDA has approved Zithromax as a once-daily, three-day treatment for acute bacterial sinusitis. Zithromax is licensed to us exclusively by Pliva, a Croatian pharmaceutical company.

• Diflucan is the world’s leading systemic antifungal. It is used to treat various fungal infections, including vaginal infections and certain infections that afflict HIV/AIDS and cancer patients with weakened immune systems. Diflucan lost patent protection in Japan and much of Europe in 2003, and the U.S. basic patent for Diflucan expired in January 2004. The FDA has granted us pediatric exclusivity with respect to Diflucan, which extends our marketing exclusivity for six months after the patent expiration date, through July 29, 2004. The FDA’s grant of pediatric exclusivity is the subject of a pending legal challenge.

• Viracept is a protease inhibitor, used in combination with other antiretroviral drugs for the treatment of HIV/AIDS infections. We market Viracept in the U.S. and Canada.

• Vfend is a treatment that can be administered orally or intravenously for certain serious and potentially fatal fungal infections. Vfend was launched in the U.S. and Europe in 2002 and has now been launched in 37 countries. In November 2003, Vfend was approved by the FDA for the treatment of esophageal candidiasis, and, in December 2003, it was approved by the FDA in an oral-suspension formulation suitable for patients unable to swallow the tablet form.

• Zyvox is for the treatment of serious Gram-positive infections in adults and children, which increasingly are caused by drug-resistant bacteria. In July 2003, the FDA approved Zyvox for the treatment of diabetic foot infections. Zyvox is available in intravenous, tablet and oral-suspension formulations.

• Spiriva is for the treatment of chronic obstructive pulmonary disease (COPD), a chronic respiratory disorder that includes chronic bronchitis and emphysema. We copromote Spiriva with Boehringer Ingelheim, which discovered and developed the drug. Spiriva has been launched in more than 40 countries, including Canada and several European countries. On January 30, 2004, the FDA approved Spiriva HandiHaler, an inhaled treatment for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD.

Urogenital Conditions

• Viagra is for the treatment of erectile dysfunction. It is the most-prescribed medicine in the world for the treatment of this condition.

• Detrol is the world’s leading product for the treatment of overactive bladder. Detrol LA is an extended-release formulation of the drug, taken once a day.


• Camptosar is one of the leading treatments for colorectal cancer.

• Ellence and Aromasin are for the treatment of breast cancer.

Eye Disease

• Xalatan is the most-prescribed glaucoma medicine in the U.S., Europe and Japan. It is for the treatment of open-angle glaucoma and ocular hypertension. Xalcom consists of Xalatan with the beta blocker timolol. In 2003, Xalatan/Xalcom became the first ophthalmic medicine to achieve $1 billion in annual sales.

• On July 24, 2003, we announced that we are exploring strategic options for our surgical ophthalmology business, including its possible sale. We acquired this business as part of Pharmacia in April 2003.

Endocrine Disorders

• Genotropin is the world’s leading human recombinant growth hormone. It is for the treatment of various growth disorders in children and adults. Novo Nordisk has granted us a non-exclusive license to sell Genotropin in the U.S.


• Zyrtec is for the treatment of year-round indoor and seasonal outdoor allergies and hives. It is indicated for use in children as young as six months old. Zyrtec is the leading branded antihistamine in the U.S. in new prescriptions and the only prescription antihistamine available in a syrup formulation. Zyrtec-D 12 Hour is the only prescription oral antihistamine/decongestant combination medicine approved to treat both year-round indoor and outdoor allergies as well as nasal congestion. Zyrtec is licensed to us by the Belgian company UCB S.A. We copromote Zyrtec as a prescription medicine in the U.S. with a subsidiary of UCB S.A., and we have a license to sell Zyrtec under various trade names as an over-the-counter (OTC) medicine in Canada, Europe, Australia and South Africa.

Other Disorders

• Medrol is used to treat hospitalized patients for chronic inflammation disorders, including arthritis and asthma.

Consumer Healthcare Segment

Our Consumer Healthcare business is one of the largest in the world. We market many of the world’s best-known OTC medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care and hair growth.

Consumer Healthcare’s principal products include:

• Listerine mouthwash

• Listerine PocketPaks oral care strips

• Nicorette for tobacco dependence

• Benadryl antihistamine for allergies

• Sudafed for sinus congestion

• Rogaine for hair growth

• Zantac 75 for prevention and relief of heartburn

• Rolaids antacid tablets

•Efferdent denture cleaner

• Neosporin antibiotic ointment

• Visine eye drops

• BenGay topical analgesic

• Cortizone skin care products

• Lubriderm moisturizing lotions

• Unisom sleep aids

• Desitin ointments for treatment of diaper rash

• Ludens throat drops

Consumer Healthcare can extend the life of some of our prescription medications by converting them to OTC medications. For example, Nicorette, Benadryl, Sudafed and Zantac 75 were all previously prescription products. As market conditions permit, and when we have necessary approval from drug regulatory authorities, we plan to pursue similar launches for other products.

Animal Health Segment

Our Animal Health business is the largest in the world. We discover, develop and sell products for the prevention and treatment of diseases in livestock and companion animals.

Parasiticides constitute the largest segment of the animal health market for companion animals, consisting mainly of medicines for the control of parasites such as fleas and heartworm. Our product, Revolution, is our largest-selling parasiticide for companion animals.

Rimadyl relieves pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery. Rimadyl is the only arthritis pain medication prescribed by veterinarians available in chewable tablets and regular caplets and in an injectable formulation.

Clavamox/Synulox is an antibiotic for dogs and cats.

Our vaccine portfolio for livestock is extensive and includes RespiSureOne/StellamuneOne, a single-dose vaccine used to prevent pneumonia in swine, and Bovi-Shield Gold, a reproductive and respiratory cattle vaccine.

Dectomax injectable and pour-on formulations remove and control internal and external parasites in beef cattle.

Naxcel/Excenel RTU is an antibiotic used to treat respiratory and internal infections in cattle and swine.

Patents and Intellectual Property Rights

U.S. Basic

Product Patent


Expiration Year

Zithromax 2005

Zoloft 2006

Norvasc 2007

Zyrtec 2007

Aricept 2010

Lipitor 2010


Viagra 2012

Detrol 2012

Celebrex 2013

Bextra 2015

Genotropin 2015



Sales by Geography Competition By Business Segments Company Profile

Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

RAIL's Profile

Stock Price

RAIL's Financials

Business Description


Charts & Quotes

RAIL's News


RAIL's Competitors

Customers & Markets

Economic Indicators

RAIL's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071